{"nctId":"NCT04752566","briefTitle":"A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome","startDateStruct":{"date":"2021-03-08","type":"ACTUAL"},"conditions":["Guillain-Barre Syndrome"],"count":57,"armGroups":[{"label":"Eculizumab","type":"EXPERIMENTAL","interventionNames":["Biological: Eculizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Eculizumab","otherNames":["Soliris"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who meet the GBS criteria.\n* Participants who were able to run prior to onset of GBS symptoms.\n* Participants with onset of weakness due to GBS \\< 2 weeks before screening.\n* Participants unable to walk unaided for ≥ 5 meters (progressively deteriorating FG3 or FG4 to FG5).\n* Participants who are already on IVIg or deemed eligible for and who will start IVIg.\n* Participants who can start their first dose of study drug before the end of the IVIg treatment period.\n\nExclusion Criteria:\n\n* Participants who have previously received or are currently receiving treatment with complement modulators.\n* Participants who have been administered another investigational product within 30 days or 5 half-lives (whichever is longer) prior to providing consent or are currently participating in another interventional study.\n* Participants who have received rituximab within 12 weeks prior to screening.\n* Participants who are being considered for or are already on plasmapheresis.\n* Participants who have received immunosuppressive treatment during the 4 weeks prior to providing consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Reaching a Hughes Functional Grade (FG) Score <=1","description":"The mobility of the participants was evaluated on a 7 point disability functional grade scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 metre (m) across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \\[for at least part of day or night\\]) and 6 (Dead), where higher numbers indicate more severe impairment. The Kaplan-Meier estimate of time to event of FG\\<=1 is reported. Time (days) to first event=Date of first event-Date of first dose+1. Participants who discontinued early without achieving FG \\<= 1 were censored at the date of discontinuation. Participants who completed the study without achieving FG\\<=1 were censored at the date of study completion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.0","spread":null},{"groupId":"OG001","value":"168.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With A Hughes Functional Grade (FG) Score <=1","description":"The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \\[for at least part of day or night\\]) and 6 (Dead), where higher numbers indicate more severe impairment. If a participant had an FG score \\<= 1 prior to or at Week 8 and Week 24, respectively, then the participant is considered a responder. Otherwise, participants discontinued prior to Week 8 and Week 24 or with an FG score \\> 1 at Week 8 and Week 24 are nonresponders, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With A Hughes Functional Grade Score Improvement of >=3","description":"The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \\[for at least part of day or night\\]) and 6 (Dead), where higher numbers indicate more severe impairment. Participants with a change from baseline in FG score (value at Week 24 - baseline value) \\<= -3 were considered a responder. Participants with change from baseline \\> -3 and participants who discontinued prior to Week 24 were considered non-responders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"TEAEs were defined as an adverse event (AE) with onset on or after the first dose of the study drug. An AE is any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Free Complement Component 5 in Serum","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131.0438","spread":"29.40068"},{"groupId":"OG001","value":"147.8833","spread":"36.70182"}]}]}]},{"type":"SECONDARY","title":"Hemolytic Complement Activity in Serum","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.79","spread":"11.077"},{"groupId":"OG001","value":"91.83","spread":"11.767"}]}]}]},{"type":"SECONDARY","title":"Length of Stay in the Hospital","description":"For participants with multiple hospitalizations, the total duration of all hospitalizations was summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":"27.15"},{"groupId":"OG001","value":"39.8","spread":"12.97"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Required Mechanical Ventilator Support","description":"For participants with more than 1 episode of the same support, the total duration across all episodes was summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Eculizumab in Serum","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.690","spread":"0.0000"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Antidrug Antibodies","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":37},"commonTop":["Insomnia","Constipation","Urinary tract infection","Headache","Pneumonia aspiration"]}}}